{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:34:24Z","timestamp":1774074864377,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bbr.2018.12.007","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T11:54:44Z","timestamp":1543838084000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"360","author":[{"given":"Simon","family":"Loiodice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Wing Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Rion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"M\u00e9ot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Montagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Denibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roselyne","family":"Viel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Drieu La Rochelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2018.12.007_bib0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson\u2019s disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbr.2018.12.007_bib0010","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1038\/tp.2016.17","article-title":"What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson\u2019s disease?","volume":"6","author":"Magnard","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbr.2018.12.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.43","article-title":"Implication of dopamine D3 receptor activation in the reversion of Parkinson\u2019s disease-related motivational deficits","volume":"4","author":"Carnicella","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbr.2018.12.007_bib0020","article-title":"Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson\u2019s disease","author":"Drui","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2018.12.007_bib0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FBP.0b013e32834aff98","article-title":"Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson\u2019s disease","volume":"22","author":"McFarland","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbr.2016.03.019","article-title":"Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson\u2019s disease","volume":"305","author":"Nezhadi","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2018.12.007_bib0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1020736131907","article-title":"The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson\u2019s disease memory disabilities","volume":"22","author":"Da Cunha","year":"2002","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuroscience.2008.08.035","article-title":"Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson\u2019s disease","volume":"156","author":"Tadaiesky","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2018.12.007_bib0045","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/jnr.21642","article-title":"Nonmotor symptoms in Parkinson\u2019s disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model","volume":"86","author":"Branchi","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbr.2018.12.007_bib0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1326-8-14","article-title":"Behavioral characterization of the 6-hydroxidopamine model of Parkinson\u2019s disease and pharmacological rescuing of non-motor deficits","volume":"8","author":"Carvalho","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbr.2018.12.007_bib0055","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.neuroscience.2008.01.084","article-title":"Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats","volume":"153","author":"Pioli","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2018.12.007_bib0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1517\/14656566.2011.587122","article-title":"An update expert opinion on management and research strategies in Parkinson\u2019s disease psychosis","volume":"12","author":"Goldman","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bbr.2018.12.007_bib0065","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1007\/s00213-015-3954-6","article-title":"The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia","volume":"232","author":"Janhunen","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2018.12.007_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.irn.2017.05.018","article-title":"Nonmotor symptoms in experimental models of parkinson\u2019s disease","volume":"133","author":"Titova","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0075","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.bbr.2018.12.007_bib0080","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","article-title":"Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa","volume":"94","author":"Bordet","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbr.2018.12.007_bib0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1460-9568.2005.04190.x","article-title":"Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism","volume":"22","author":"Brown","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2018.12.007_bib0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1471-4159.2007.04586.x","article-title":"Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum","volume":"102","author":"Bychkov","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2018.12.007_bib0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbr.2018.12.007_bib0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.26121","article-title":"Behavioral effects of levodopa","volume":"30","author":"Beaulieu-Boire","year":"2015","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.bbr.2018.12.007_bib0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.wco.0000137528.23126.41","article-title":"Dopamine dysregulation syndrome in Parkinson\u2019s disease","volume":"17","author":"Evans","year":"2004","journal-title":"Curr. Opin. Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.bbr.2018.12.007_bib0110","article-title":"Drug-induced psychotic symptoms in Parkinson\u2019s disease. Problems, management and dilemma","volume":"248","author":"Kuzuhara","year":"2001","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0115","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.26731","article-title":"The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations","volume":"31","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"Suppl 3","key":"10.1016\/j.bbr.2018.12.007_bib0120","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10513","article-title":"Limitations of current Parkinson\u2019s disease therapy","volume":"53","author":"Rascol","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-016-4430-7","article-title":"Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications","volume":"15\u201327","author":"Loiodice","year":"2017","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2018.12.007_bib0130","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/0269881117714051","article-title":"Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson\u2019s disease","volume":"31","author":"Loiodice","year":"2017","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.bbr.2018.12.007_bib0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbr.2017.06.016","article-title":"Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area","volume":"332","author":"Dardou","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2018.12.007_bib0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/FBP.0b013e32833e7e80","article-title":"Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat","volume":"21","author":"Eskow Jaunarajs","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","article-title":"Potential mechanisms underlying anxiety and depression in Parkinson\u2019s disease: consequences of l-DOPA treatment","volume":"35","author":"Eskow Jaunarajs","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbr.2018.12.007_bib0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuroscience.2012.05.052","article-title":"L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson\u2019s disease","volume":"218","author":"Eskow Jaunarajs","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2018.12.007_bib0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2013.11.013","article-title":"Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations","volume":"82","author":"Hern\u00e1ndez","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2018.12.007_bib0160","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.bbr.2018.12.007_bib0165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/acschemneuro.7b00426","article-title":"Validation of a new scoring scale for behavioral assessment of L-Dopa-Induced dyskinesia in the rat: a new tool for early decision-making in drug development","volume":"9","author":"Loiodice","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbr.2018.12.007_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135949","article-title":"Behavioural assessment of the A2a\/NR2B combination in the unilateral 6-OHDA-Lesioned rat model: a new method to examine the therapeutic potential of non-dopaminergic drugs","volume":"10","author":"Michel","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2018.12.007_bib0175","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1046\/j.1460-9568.2000.00089.x","article-title":"Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats","volume":"12","author":"Bordet","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2018.12.007_bib0180","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.jnen.0000186922.42592.b7","article-title":"Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats","volume":"64","author":"Sgambato-Faure","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0306-4522(02)00548-1","article-title":"Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa","volume":"116","author":"van Kampen","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2018.12.007_bib0190","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mds.21308","article-title":"Rat model of Parkinson\u2019s disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias","volume":"22","author":"Paill\u00e9","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2018.12.007_bib0195","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF02253541","article-title":"Trial 2 in the elevated plus-maze: a different form of fear?","volume":"111","author":"File","year":"1993","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2018.12.007_bib0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2008.07.020","article-title":"Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat","volume":"194","author":"Jenkins","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2018.12.007_bib0205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1124\/jpet.117.245506","article-title":"Phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-Methyl-d-Aspartate receptor antagonist-induced rat models of schizophrenia","volume":"365","author":"Nakashima","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2018.12.007_bib0210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cne.903310302","article-title":"Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat","volume":"331","author":"German","year":"1993","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bbr.2018.12.007_bib0215","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","article-title":"The 6-hydroxydopamine model: news from the past","volume":"14","author":"Blandini","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbr.2018.12.007_bib0220","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.nbd.2011.10.023","article-title":"Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism","volume":"45","author":"Delaville","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2018.12.007_bib0225","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fnbeh.2014.00290","article-title":"A mouse model of non-motor symptoms in Parkinson\u2019s disease: focus on pharmacological interventions targeting affective dysfunctions","volume":"8","author":"Bonito-Oliva","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.bbr.2018.12.007_bib0230","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nbd.2015.07.010","article-title":"The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation","volume":"82","author":"Faggiani","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2018.12.007_bib0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbr.2007.07.002","article-title":"Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats","volume":"184","author":"Winter","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2018.12.007_bib0240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","article-title":"Advances in markers of prodromal Parkinson disease","volume":"12","author":"Postuma","year":"2016","journal-title":"Nat. Rev. Neurol."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432818312981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432818312981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T09:18:52Z","timestamp":1546593532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432818312981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":48,"alternative-id":["S0166432818312981"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2018.12.007","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}